Results 111 to 120 of about 21,298 (206)

AGO Recommendations for Diagnosis and Treatment of Patients with Early and Metastatic Breast Cancer: Update 2012 [PDF]

, 2011
Harbeck, Nadia, Scharl, Anton, Thomssen, Christoph   +2 more
core   +2 more sources

Randomized phase II trial of fulvestrant alone or in combination with bortezomib in hormone receptor-positive metastatic breast cancer resistant to aromatase inhibitors: A New York Cancer Consortium trial [PDF]

, 2016
et al,, Ma, Cynthia X, Naughton, Michael
core   +2 more sources

Beyond CDK4/6 Inhibition: Current Strategies in Hormone Receptor-Positive Metastatic Breast Cancer. [PDF]

Curr Treat Options Oncol
Cetin B, Erdem D, Karaman I, Gumusay O.
europepmc   +1 more source

Functional annotation of ESR1 gene fusions in estrogen receptor-positive breast cancer [PDF]

, 2018
Crowder, Robert, Davies, Sherri R, et al,, Hoog, Jeremy, Iglesia, Michael, Li, Shunqiang, Ma, Cynthia X, Maher, Christopher A, Phommaly, Chanpheng, Rogers, Anna, Shao, Jieya, Watson, Mark A, Zhang, Jin   +12 more
core   +1 more source

The Selective Estrogen Receptor Degrader ZN-c5 Has Broad Antitumor Activity in Wild-Type and Mutant ER-Positive Breast Cancer Models. [PDF]

Mol Cancer Ther
Ma J, Hegde S, Sergeeva M, Chakraborty B, Wardell SE, McDonnell DP, Huang PQ, Bunker KD, Doñate F, Lackner MR, Samatar AA.   +10 more
europepmc   +1 more source

Patient-reported outcomes and qualitative interviews in patients with estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: results from the phase III EMBER-3 trial. [PDF]

ESMO Open
Curigliano G, O'Shaughnessy J, Bidard FC, Casalnuovo ML, Kim SB, Tokunaga E, Aftimos P, Saura C, Carey LA, Okera M, Melo E, Zagouri F, Magallanes-Maciel M, Karadurmus N, Bahadur S, Speck RM, Wang XA, Pradhan K, Macey J, Kitchen H, Fairhurst S, Miller J, Jhaveri KL, Harbeck N.   +23 more
europepmc   +1 more source

Imlunestrant plus abemaciclib versus fulvestrant plus abemaciclib in ER-positive, HER2-negative advanced breast cancer: an indirect treatment comparison of three phase III trials. [PDF]

ESMO Open
Jhaveri K, Bidard FC, Kalinsky K, Neven P, Rugo HS, Tolaney SM, Litchfield LM, von Laue CC, Traore S, Sapunar F, Li Y, O'Shaughnessy J.   +11 more
europepmc   +1 more source

VIKTORIA-1 Trial of Gedatolisib Plus Fulvestrant With or Without Palbociclib in Hormone Receptor-Positive/HER2-/PIK3CA Wild-Type Advanced Breast Cancer. [PDF]

J Clin Oncol
Hurvitz SA, Layman RM, Curigliano G, André F, Cristofanilli M, Kim SB, Martínez Rodríguez JL, Nadal JC, Kim GM, Lo L, Remolina-Bonilla YA, Rosselli G, Emile G, Korbenfeld E, Puig JM, Wesolowski R, Martin M, Ring A, Han HS, Giordano A, Mutka SC, Moss K, Suzuki S, Sullivan B, Gorbatchevsky I, Pistilli B, VIKTORIA-1 Study Group.   +26 more
europepmc   +1 more source

Mining of Respiratory System Toxicity Risk Signals for Fulvestrant Based on the Tianjin Adverse Reaction Monitoring Center and the FDA Adverse Event Reporting System Database. [PDF]

Hosp Pharm
Wang M, Han Q, Jiang Y, Liang G, Yang F.
europepmc   +1 more source

Identification of Resistance Genes in Breast Cancer Cells Treated with Fulvestrant and Ribociclib via Retroviral Screening and Integration Site Sequencing. [PDF]

Cells
Huang Z, Beaufort C, Helmijr J, Zantboer B, Rozema G, Muritti C, Whien JJ, Uijterwegen A, Massimino M, Martens JWM, Jansen MPHM.   +10 more
europepmc   +1 more source